Search Results

You are looking at 1 - 10 of 53 items for :

  • Endocrinology, Diabetology x
Clear All
Open access

Toshiki Kan, Senju Hashimoto, Naoto Kawabe, Takuji Nakano, Kazunori Nakaoka and Kentaro Yoshioka

factors associated with ≥ 0.3 g/dL increase in albumin levels in groups B and C. The only factor associated with ≥ 0.3 g/dL increase in albumin levels was the baseline AST level. We also showed that a decrease in AST levels was significantly associated with an increase in albumin levels. In healthy subjects, the albumin turnover time is approximately 25 days, and it reflects a liver albumin synthesis rate of approximately 10.5 g/day, balanced by renal (6%), gastrointestinal (10%), and catabolic (84%) clearances.[ 17 ] Since only 20-30% of hepatocytes are committed to

Open access

Amal Ahmed Mohamed, Eman R. Abd Almonaem, Amira I. Mansour, HebatAllah Fadel Algebaly, Rania Abdelmonem Khattab and Yasmine S. El Abd

= 18.54 <0.001 (HS) H/F 0.12 ± 0.06 0.02–0.25 0.68 ± 0.69 0.03–4.00 Z = 5.04 <0.001 (HS) Platelet count (cells/μL) 182.94 ± 53.88 102–300 448,320 ± 656,562.1 180,000–3,000,000 Z = 8.63 <0.001 (HS) Hb (g/dL) 11.14 ± 1.06 9–13 11.88 ± 1.7 9–15 t = 2.60 0.01 (S) WBC count (cells/μL) 5,204.56 ± 1,684.55 2,300–8,900 7,196 ± 2,282.4 2500–12,000 t = 4.96 <0.001 (HS) Hepcidin expression 4.72 ± 3.14 1–11 10.34 ± 3.47 4–18 t = 8.49 <0.001 (HS) ALT: alanine transaminase; AST

Open access

Tingxue Song, Zhe Jia, Xiaozhong Guo, Haitao Zhao, Wenchun Bao, Dan Han, Xinmiao Zhou and Xingshun Qi

General Hospital of Military Area from February 2016 to November 2017 were eligible. We collected the data regarding renal and hepatic function parameters, which were detected at the same time during hospitalization. The normal ranges of laboratory tests were: SCr (44–133 μmol/L), Cystatin C (0–1.03 mg/L) and serum β 2 microglobulin (0.9–3mg/L). Statistical analyses were performed using SPSS version 20.0.0 software (SPSS Inc., Chicago, IL, USA). Continuous data were expressed as mean ± standard deviation (SD) and median (range). Categorical data were expressed as

Open access

Ebada Said, Waleed El Agawy, Rehab Ahmed, Mohamed Hassany, Amal Ahmed, Hanan Fouad and Hosam Baiumy

III ( n = 25) P value Age (years) 40.25 ± 9.46 38.22 ± 9.64 38.4 ± 10.42 0.58 Gender (males/females), n (%) 30(62)/18(38) 31(64)/17(36) 15(60)/10(40) 0.45 BMI (kg/m 2 ) 30.55 ± 4.63 30.65 ± 4.45 28.8 ± 3.12 0.16 AST (IU/L) 23.7 ± 10.54 43.7 ± 22.4 29.7 ± 8.40 < 0.001 ALT (IU/L) 20.7 ± 9.5 53.1 ± 27.68 27.5 ± 6.13 < 0.001 Bilirubin (mg/dL) 0.81 ± 0.26 0.79 ± 0.27 0.75 ± 0.20 0.69 Albumin (g/dL) 4.34 ± 0.33 4.09 ± 0.49 4.49 ± 0.46 < 0.001 PT (s) 13.2 ± 0

Open access

Ming Hong and Guangsheng He

classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-51. 10.1182/blood-2009-03-209262 Vardiman JW Thiele J Arber DA Brunning RD Borowitz MJ Porwit A The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 2009 114 937 51 3 Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al . International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89: 2079–88. Greenberg P Cox C LeBeau MM Fenaux P Morel P

Open access

Bennur Esen, Emel Sağlam Gokmen, Mahmut Kaya, Burak Ozkan and Ahmet Engin Atay

.09 ± 1.26 (1.75) 2.72 ± 2.75 (2) a Mann-Whitney U test; 0.367 Insulin (mU/L) 12.03 ± 7.53 (11.03) 11.08 ± 7.93 (8.79) a Mann-Whitney U test; 0.232 WBC (/mm 3 ) 7.12 ± 1.85 (7.06) 7.25 ± 2.20 (6.97) a Mann-Whitney U test; 0.929 HGB (g/dL) 13.49 ± 1.77 13.89 ± 1.66 b Student’s t -test; 0.172 HCT (%) 41.46 ± 5.11 42.64 ± 4.57 b Student’s t -test; 0.164 PLT (/mm 3 ) 241.29 ± 62.38 249.86 ±59.89 b Student’s t -test; 0.417 MPV (fL) 7.87 ± 1.31 8.16 ± 1.80 b Student’s t -test; 0.267 Urine

Open access

Gianluca Rigatelli, Marco Zuin, Tra T. Ngo, Hung T. Nguyen, Aravinda Nanjundappa, Ernest Talarico, Le Cao Phuong Duy and Thach Nguyen

the coronary angiography (CA) was used to determine the serum total cholesterol (TC), triglycerides (TG) and high-density lipoprotein (HDL). LDL-C concentrations were calculated using the Friedewald formula. Body mass index (BMI) was calculated (in kg/m 2 ) as the ratio of weight to squared height. The subjects were considered to be overweight if the body mass index was between 25 and 29.9 kg/m 2 and obese if ≥ 30 kg/m 2 . Patients were labelled as having impaired fasting glucose, if it was between 100 and 125.9 mg/dL, and as diabetic, if it was repeatedly ≥ 126 mg

Open access

Ştefania Dumitrescu

diary. IEEE Trans Inf Technol Biomed 14: 456-63, 2010. 16. Tsai CC, Lee G, Raab F et al. Usability and feasibility of PmEB: A mobile phone application for monitoring real time caloric balance. In: 2006 Pervasive Health Conference and Workshops, IEEE, pp. 1 -10, 2006. http://ieeexplore.ieee.org/lpdocs/epic03/wrapper.htm?arnumber=4205150 17. Tran J, Tran R, White JR. Smartphone-based glucose monitors and applications in the management of diabetes: An overview of 10 salient ‘apps’ and a novel smartphone-connected blood glucose monitor. Clin Diabetes 30: 173

Open access

Ionuţ Vlad and Amorin Remus Popa

diabetes in Finnish children: a cohort study. Lance t 371: 1777-1782, 2008. 32. Tîrgovişte CI, Lichiardopol R, Dobjanschi C, Guja C., Culman M., Bradescu O., Bojin A. Diabetul zaharat tip 2 ghid terapeutic pentru medicul de familie. Jurnalul Român de Diabet. Nutriţie şi Boli Metabolice 13: 220-245, 2006. 33. http://www.who.int/diabetes/publications/en/screening_mnc03.pdf 34. World Health Organization. Causes of death 2008: data sources and methods. Geneva, World Health Organization , 2010. 35. Roglic G, Unwin N

Open access

Sakiko Yamane, Chikatoshi Katada, Satoshi Tanabe, Mizutomo Azuma, Kenji Ishido, Takafumi Yano, Takuya Wada, Akinori Watanabe, Natsuko Kawanishi, Yasuaki Furue, Yuki Kondo, Shouko Komori, Hiromichi Ishiyama, Kazushige Hayakawa and Wasaburo Koizumi

. Management of “unfavourable” carcinoma of unknown primary site: synthesis of recent literature.Crit Rev OncolHematol2012; 84: 213-23. 10.1016/j.critrevonc.2012.03.003 Amela EY Lauridant-Philippin G Cousin S Ryckewaert T Adenis A Penel N. Management of “unfavourable” carcinoma of unknown primary site: synthesis of recent literature Crit Rev OncolHematol 2012 84 213 23 10 Culine S, Ychou M, Fabbro M, Romieu G, Cupissol D. 5-fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site. Anticancer Res 2001; 21